Safety warnings and messages for medicines

Frequent visitors should click the Refresh button to ensure that the latest version of this page is displayed.

Latest safety warnings and messages for medicines

• 01 Feb 2010 | Nicotine replacement therapy: New extended indication and consultation
  

  We have today announced an extended indication for nicotine replacement therapy (NRT) to include harm reduction, which has been granted for an (NRT) inhalator, available through general sales outlets.

• 01 Feb 2010 | Information sent to healthcare professionals in January 2010 about the safety of medicines
  

  A list of letters sent to healthcare professionals in January 2010, to inform of new safety information and advice.

• 21 Jan 2010 | Sibutramine: Suspension of marketing authorisation as risks outweigh benefits
  

  The European Medicines Agency (EMA) has completed a review of the obesity medicine sibutramine (Reductil). The review has found that the cardiovascular risks of sibutramine outweigh its benefits.

• 04 Jan 2010 | Information sent to healthcare professionals in December 2009 about the safety of medicines
  

  A list of letters sent to healthcare professionals in December 2009, to inform of new safety information and advice.

• 03 Dec 2009 | Warfarin: changes to safety information
  

  Following a UK review of adverse drug reaction reports, published literature and current practice guidelines, the safety sections in the product information for warfarin will be amended to give clearer, up-to-date advice.

• 03 Dec 2009 | Finasteride and the risk of male breast cancer
  

  A Europe-wide review of clinical trial data, adverse drug reaction reports and published literature has concluded that an increased risk of male breast cancer associated with finasteride use cannot be excluded.

• 01 Dec 2009 | Information sent to healthcare professionals in November 2009 about the safety of medicines
  

  A list of letters sent to healthcare professionals in November 2009, to inform of new safety information and advice.

• 04 Nov 2009 | Information sent to healthcare professionals in October 2009 about the safety of medicines
  

  A list of letters sent to healthcare professionals in October 2009, to inform of new safety information and advice.

• 03 Nov 2009 | Statins: Updates to product safety information
  

  Statins are medicines widely used to treat people with high levels of cholesterol and triglycerides (fats) in their blood. A Europe-wide review of clinical trial data, adverse drug reaction reports and published literature on statins has concluded that various adverse reactions may be associated with statin use.

• 03 Nov 2009 | Orciprenaline sulphate: Planned withdrawal from the UK market following a risk-benefit analysis
  

  Orciprenaline sulphate (Alupent Syrup) is a medicine used to treat airway obstruction seen in conditions such as asthma. A review of orciprenaline sulphate recently conducted by the MHRA showed that the balance of its benefits and risks is no longer favourable. Therefore, this medicine will be withdrawn from the market over the next year.